Sticta Smart Insulin

Sticta Smart Insulin is a recombinant single-chain insulin specifically engineered to replace conventional insulin in serum-free media for animal cell culture. It addresses the high costs and logistical complexities associated with pharmaceutical-grade growth factors by providing a high-volume, cost-effective alternative for cultivated meat and biopharmaceutical applications. This species-agnostic protein promotes robust glucose uptake and cell proliferation across diverse mammalian and immortalised cell lines.

Developed through an advanced protein engineering pipeline, Sticta Smart Insulin is tailored for superior solubility and thermostability. It eliminates the need for strict cold-chain logistics, allowing storage and shipment at room temperature without loss of bioactivity. Produced using Pichia pastoris (Komagataella phaffii) via precision fermentation, the manufacturing process ensures high yields at a cost approximately 10× lower than traditional recombinant insulin.

Performance has been validated across multiple relevant cell types, including C2C12 myoblasts and bovine fibroblasts. In trials with porcine iPSCs, the product maintained pluripotency marker expression (OCT4, SOX2, and NANOG) above 90% over five passages. Targeted proteomic analysis confirmed that no insulin residues were detected in final cell-cultured bovine muscle or fat biomass, supporting its use in food production.

Supplied as a spray-dried white powder, Sticta Smart Insulin offers exceptional solubility of up to in standard PBS buffer. it is formulated with 2% trehalose in a phosphate buffer and is stable at -20°C for three months or at for one year. The recommended working concentration ranges from 0.1 mg/L, depending on the specific media formulation.

This product is suitable for bovine, porcine, fish, and human cell cultivation from R&D through to commercial-scale manufacturing. It is intended for further manufacturing or laboratory use and is compatible with all serum-free culture media.